Citicoline

JFDA label: Somazina Inj

Indications

Off-label

• Alcoholism
• Amphetamine-Related Disorders
• Attention Deficit Disorder with Hyperactivity
• Brain Injuries
• Brain Ischemia
• Cerebral Infarction
• Glaucoma, Open-Angle
• Ischemic Stroke
• Marijuana Abuse
• Stroke

Chemistry & Properties

Formula	C14H26N4O11P2
Molecular weight	488.33 g/mol
IUPAC name	[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate
CAS	987-78-0
PubChem CID	13804
InChIKey	RZZPDXZPRHQOCG-OJAKKHQRSA-N
logP	-2.23 (XLogP -4.0)
Polar surface area	215.72 Ų
H-bond acceptors / donors	13 / 4
Drug-likeness (QED)	0.20
Lipinski violations	1

SMILES

C[N+](C)(C)CCOP(=O)(O)OP(=O)([O-])OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O

Biology & Pharmacokinetics

Pharmacokinetics predicted

Bioavailability	70.0%
Half-life	1.769 h
Volume of distribution	0.282 L/kg
Protein binding	16.6%
BBB penetrant	No

Enzyme interactions

Enzyme	Role	Detail
CYP2C9	Substrate	—

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)

Registered Products (7)

Brand	Form / strength	Pack	Agent	Citizen (JOD)
Somazina Inj	Powder for Injection 500 mg	5 amp	Ibn Rushd Drug Store	3.290
Momizal	Solution 100 mg/ml	30 ml	Dar Al Dawa Development and Investment Co Ltd/Jordan	3.920
Somacita	Solution 100 mg/1 ml	30 ml pack varies	Al-Motakadema Pharmaceutical LTD.	3.930
Somazina Oral Sol	Solution 100 mg/ml	10 sachet pack varies	Itqan Pharmaceutical Industries/Jordan	16.630
Somacita	Solution 100 mg/1 ml	150 ml pack varies	Al-Motakadema Pharmaceutical LTD.	18.080
Somacita	Solution 100 mg/1 ml	300 ml pack varies	Al-Motakadema Pharmaceutical LTD.	35.370
Somazina Oral Sol	Solution 100 mg/ml	30 sachet pack varies	Itqan Pharmaceutical Industries/Jordan	43.910